SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

This phase I trial tests the safety, side effects, and best dose of SNDX-5613 and gilteritinib for treating patients with acute myeloid leukemia that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and has a mutation in the FLT3 gene along with either a mutation in the NMP1 gene or a type of mutation called a rearrangement in the MLL gene. SNDX-5613 is in a class of medications called menin inhibitors. It works by blocking the action of mutated MLL and NMP1 proteins that signal cancer cells to multiply. Gilteritinib is in a class of med

Trial Details

NCT ID
NCT06222580
Phase
PHASE1
Sponsor
Uma Borate
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Biospecimen Collection
  • Bone Marrow Aspiration and Biopsy
  • Gilteritinib
  • Revumenib
  • Echocardiography Test
  • Multigated Acquisition Scan
Locations (sample)
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362
  • Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

  • Signed informed consent must be obtained prior to participation in the study
  • Age ≥ 18 years at the date of signing the informed consent form (ICF)
  • Morphologically confirmed diagnosis of the following based on 2022 World Health Organization (WHO) classification:
  • Relapsed or Refractory Acute Myeloid Leukemia with the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →